https://sciencelibrary.sobi.com/ 2025-01-07T15:55:52+01:00 daily 1.0 https://sciencelibrary.sobi.com/isth-2024-congress-thrombosis-and-hemostasis-conference 2025-05-14T11:34:57+02:00 0.5 https://sciencelibrary.sobi.com/eahad-2025-18th-annual-eahad-congress 2025-06-02T10:44:43+02:00 0.5 https://sciencelibrary.sobi.com/asn-kidney-week-2024 2025-05-19T12:48:00+02:00 0.5 https://sciencelibrary.sobi.com/66th-ash-annual-meeting-and-exposition 2025-06-02T10:45:10+02:00 0.5 https://sciencelibrary.sobi.com/29th-european-hematology-association-congress 2025-05-14T11:35:07+02:00 0.5 https://sciencelibrary.sobi.com/ispor-europe-2024 2025-06-02T10:44:16+02:00 0.5 https://sciencelibrary.sobi.com/acr-convergence-2024 2025-06-05T15:05:47+02:00 0.5 https://sciencelibrary.sobi.com/1st-european-research-consortium-itp-meeting-erci-2024 2025-06-05T15:04:33+02:00 0.5 https://sciencelibrary.sobi.com/31st-annual-pres-meeting 2025-06-02T10:45:58+02:00 0.5 https://sciencelibrary.sobi.com/histiocyte-society-annual-meeting-2024 2025-06-05T15:06:07+02:00 0.5 https://sciencelibrary.sobi.com/soho-2024 2025-06-05T15:06:41+02:00 0.5 https://sciencelibrary.sobi.com/2024-asco-annual-meeting 2024-12-17T13:53:47+01:00 0.5 https://sciencelibrary.sobi.com/european-congress-rheumatology 2025-06-05T15:07:25+02:00 0.5 https://sciencelibrary.sobi.com/nccn-2025-annual-conference 2025-03-31T09:44:55+02:00 0.5 https://sciencelibrary.sobi.com/wfh-2025-comprehensive-care-summit 2025-05-19T12:51:42+02:00 0.5 https://sciencelibrary.sobi.com/htrs-2025-scientific-symposium 2025-03-14T15:41:46+01:00 0.5 https://sciencelibrary.sobi.com/20th-congress-international-pediatric-nephrology-association 2025-03-03T10:56:43+01:00 0.5 https://sciencelibrary.sobi.com/62nd-era-congress 2025-06-04T09:18:36+02:00 0.5 https://sciencelibrary.sobi.com/international-symposium-intensive-care-emergency-medicine 2025-05-06T09:50:31+02:00 0.5 https://sciencelibrary.sobi.com/30th-european-hematology-association-congress 2025-06-04T09:38:39+02:00 0.5 https://sciencelibrary.sobi.com/ispor-2025 2025-06-04T09:37:35+02:00 0.5 https://sciencelibrary.sobi.com/congress-clinical-rheumatology-east-2025 2025-06-02T10:43:00+02:00 0.5 https://sciencelibrary.sobi.com/british-society-haematology-65th-annual-scientific-meeting 2025-05-06T09:05:42+02:00 0.5 https://sciencelibrary.sobi.com/2025-aspho-conference 2025-11-05T18:10:56+01:00 0.5 https://sciencelibrary.sobi.com/33rd-congress-international-society-thrombosis-and-haemostasis 2025-06-25T10:37:30+02:00 0.5 https://sciencelibrary.sobi.com/2nd-ipig-conference-international-pnh-interest-group 2025-05-06T09:48:42+02:00 0.5 https://sciencelibrary.sobi.com/eular-2025-congress 2025-06-14T16:24:08+02:00 0.5 https://sciencelibrary.sobi.com/ascpt-2025-annual-meeting 2025-05-14T11:38:12+02:00 0.5 https://sciencelibrary.sobi.com/53rd-annual-meeting-european-working-group-psychosocial-aspects-children-chronic-kidney-disease 2025-06-14T16:24:36+02:00 0.5 https://sciencelibrary.sobi.com/international-society-systemic-autoinflammatory-diseases-2025 2025-05-19T12:49:47+02:00 0.5 https://sciencelibrary.sobi.com/american-nephrology-nurses-association-national-summit 2025-06-02T10:43:08+02:00 0.5 https://sciencelibrary.sobi.com/2025-asco-annual-meeting 2025-11-05T18:10:32+01:00 0.5 https://sciencelibrary.sobi.com/18th-international-conference-malignant-lymphoma 2025-10-17T13:32:44+02:00 0.5 https://sciencelibrary.sobi.com/57th-annual-meeting-european-society-paediatric-nephrology 2025-09-22T17:46:51+02:00 0.5 https://sciencelibrary.sobi.com/15th-international-podocyte-conference-and-isgd-meeting 2025-11-05T18:10:21+01:00 0.5 https://sciencelibrary.sobi.com/world-transplant-congress-2025 2026-02-17T15:59:51+01:00 0.5 https://sciencelibrary.sobi.com/13th-congress-international-pediatric-transplant-association 2026-02-17T15:59:20+01:00 0.5 https://sciencelibrary.sobi.com/13th-annual-meeting-society-hematologic-oncology-soho-2025 2025-10-17T13:33:23+02:00 0.5 https://sciencelibrary.sobi.com/27th-asia-pacific-league-associations-rheumatology-congress 2026-02-17T15:59:38+01:00 0.5 https://sciencelibrary.sobi.com/32nd-european-paediatric-rheumatology-congress 2025-11-05T18:09:31+01:00 0.5 https://sciencelibrary.sobi.com/bic-international-conference 2025-10-17T13:34:03+02:00 0.5 https://sciencelibrary.sobi.com/acr-convergence-2025 2025-10-08T13:36:51+02:00 0.5 https://sciencelibrary.sobi.com/asn-kidney-week-2025 2025-11-05T16:19:44+01:00 0.5 https://sciencelibrary.sobi.com/87th-annual-meeting-japanese-society-hematology 2026-01-19T17:43:20+01:00 0.5 https://sciencelibrary.sobi.com/academy-managed-care-pharmacy-nexus 2026-02-23T12:03:01+01:00 0.5 https://sciencelibrary.sobi.com/2025-accp-annual-meeting 2026-02-23T12:03:10+01:00 0.5 https://sciencelibrary.sobi.com/67th-ash-annual-meeting-and-exposition 2025-10-28T10:43:35+01:00 0.5 https://sciencelibrary.sobi.com/lxvii-congreso-nacional-sehh-xli-congreso-nacional-seth 2026-02-17T15:59:07+01:00 0.5 https://sciencelibrary.sobi.com/world-congress-nephrology 2025-12-10T10:16:29+01:00 0.5 https://sciencelibrary.sobi.com/eahad-2026-19th-annual-congress-european-association-haemophilia-and-allied-disorders 2026-02-06T12:24:15+01:00 0.5 https://sciencelibrary.sobi.com/pediatric-rheumatology-symposium-2026 2026-03-31T13:44:45+02:00 0.5 https://sciencelibrary.sobi.com/45th-international-symposium-intensive-care-and-emergency-medicine 2026-03-31T12:34:59+02:00 0.5 https://sciencelibrary.sobi.com/european-crystal-network-workshop-2026 2026-02-10T15:07:36+01:00 0.5 https://sciencelibrary.sobi.com/52nd-annual-meeting-ebmt 2026-04-01T10:25:03+02:00 0.5 https://sciencelibrary.sobi.com/wfh-2026-world-congress 2026-04-01T10:25:35+02:00 0.5 https://sciencelibrary.sobi.com/congress-clinical-rheumatology-east-2026 2026-04-01T10:25:44+02:00 0.5 https://sciencelibrary.sobi.com/34th-congress-international-society-thrombosis-and-haemostasis 2026-03-30T17:17:30+02:00 0.5 https://sciencelibrary.sobi.com/63rd-era-congress 2026-03-30T17:41:07+02:00 0.5 https://sciencelibrary.sobi.com/american-society-clinical-pharmacology-therapeutics-2026-annual-meeting 2026-03-31T15:49:58+02:00 0.5 https://sciencelibrary.sobi.com/exploring-future-macrophage-activation-syndrome-stills-disease 2025-04-28T14:56:42+02:00 0.5 https://sciencelibrary.sobi.com/long-term-joint-health-outcomes-recombinant-factor-viii-fc-48-month-prospective-observational-more 2024-12-02T15:08:31+01:00 0.5 https://sciencelibrary.sobi.com/effectiveness-and-safety-efmoroctocog-alfa-recombinant-factor-viii-fc-across-body-mass-index-bmi 2024-12-11T15:01:22+01:00 0.5 https://sciencelibrary.sobi.com/using-hemophilia-functional-ability-scoring-tool-hemo-fast-describe-joint-health-status-adults 2024-12-11T15:49:37+01:00 0.5 https://sciencelibrary.sobi.com/valiant-phase-3-trial-pegcetacoplan-patients-native-or-post-transplant-recurrent-c3g-or-primary-ic 2024-11-26T12:09:32+01:00 0.5 https://sciencelibrary.sobi.com/association-between-hemophilia-joint-health-score-and-quality-life-using-results-xtend-1 2024-12-13T10:31:02+01:00 0.5 https://sciencelibrary.sobi.com/retrospective-analysis-pacritinib-treatment-outcomes-myelofibrosis-patients-and-without-monocytosis 2024-12-04T14:15:07+01:00 0.5 https://sciencelibrary.sobi.com/phase-3-randomised-double-blind-placebo-controlled-trial-evaluate-efficacy-and-safety-avatrombopag 2024-12-11T15:50:35+01:00 0.5 https://sciencelibrary.sobi.com/loncastuximab-tesirine-versus-glofitamab-treatment-relapsedrefractory-diffuse-large-b-cell-lymphoma 2025-01-07T15:27:59+01:00 0.5 https://sciencelibrary.sobi.com/phase-4-adopt-study-interim-analysis-efficacy-and-safety-results-avatrombopag-treatment-adult 2024-12-11T15:03:52+01:00 0.5 https://sciencelibrary.sobi.com/first-interim-analysis-clinical-outcomes-adults-and-adolescents-severe-hemophilia-receiving 2024-12-11T15:43:05+01:00 0.5 https://sciencelibrary.sobi.com/long-term-outcomes-efanesoctocog-alfa-prophylaxis-previously-treated-children-severe-hemophilia 2024-12-13T10:58:27+01:00 0.5 https://sciencelibrary.sobi.com/interim-analysis-joint-outcomes-adult-and-adolescent-patients-severe-hemophilia-receiving 2024-12-11T15:41:25+01:00 0.5 https://sciencelibrary.sobi.com/perioperative-management-efanesoctocog-alfa-adults-adolescents-and-children-severe-hemophilia-phase 2025-01-07T12:01:01+01:00 0.5 https://sciencelibrary.sobi.com/improvements-patient-reported-outcomes-after-treatment-sel-212-adults-refractory-gout-results-two 2025-01-10T16:33:14+01:00 0.5 https://sciencelibrary.sobi.com/safety-and-efficacy-sel-212-us-and-ex-us-subgroups-results-phase-3-dissolve-studies 2025-06-12T13:48:08+02:00 0.5 https://sciencelibrary.sobi.com/impact-anti-drug-antibodies-efficacy-sel-212-patients-chronic-gout-refractory-conventional-therapy 2024-12-12T11:08:14+01:00 0.5 https://sciencelibrary.sobi.com/efficacy-and-safety-sel-212-patients-refractory-gout-and-chronic-kidney-disease-post-hoc-analysis 2024-12-12T11:14:07+01:00 0.5 https://sciencelibrary.sobi.com/impact-thrombopoietin-receptor-agonist-treatment-and-adherence-patients-primary-chronic-immune 2024-12-12T12:02:51+01:00 0.5 https://sciencelibrary.sobi.com/european-retrospective-study-describe-real-world-outcomes-patients-primary-immune-thrombocytopenia 2024-12-12T12:13:17+01:00 0.5 https://sciencelibrary.sobi.com/real-world-paterns-additional-factor-treatment-use-among-hemophilia-patients-regular-prophylaxis 2024-12-12T17:10:33+01:00 0.5 https://sciencelibrary.sobi.com/unmet-needs-factor-consumption-and-healthcare-resource-use-among-people-hemophilia-real-world 2024-12-12T17:11:21+01:00 0.5 https://sciencelibrary.sobi.com/use-avatrombopag-patients-immune-thrombocytopenia-interim-analysis-phase-4-adopt-study 2024-12-12T17:13:40+01:00 0.5 https://sciencelibrary.sobi.com/analysis-durability-response-avatrombopag-ava-phase-3b-multicenter-randomized-double-blind-placebo 2024-12-12T17:02:25+01:00 0.5 https://sciencelibrary.sobi.com/enhanced-patient-satisfaction-and-stability-platelet-counts-following-switch-eltrombopag-elt-or 2024-12-12T17:09:03+01:00 0.5 https://sciencelibrary.sobi.com/results-prospective-open-label-phase-4-study-evaluating-safety-efficacy-and-treatment-satisfaction 2024-12-12T17:08:26+01:00 0.5 https://sciencelibrary.sobi.com/real-world-treatment-patterns-and-outcomes-patients-primary-immune-thrombocytopenia-treated 2024-12-12T17:03:47+01:00 0.5 https://sciencelibrary.sobi.com/ava-307-additonal-efficacy-efficacy-and-safety-avatrombopag-japanese-adults-chronic-immune 2025-03-26T16:04:51+01:00 0.5 https://sciencelibrary.sobi.com/clinical-outcomes-over-3-years-once-weekly-efanesoctocog-alfa-treatment-adults-and-adolescents 2024-12-12T17:14:35+01:00 0.5 https://sciencelibrary.sobi.com/real-world-experience-switching-prophylactic-efanesoctocog-alfa-patients-moderate-or-severe 2024-12-12T17:12:29+01:00 0.5 https://sciencelibrary.sobi.com/cost-comparison-efanesoctocog-alfa-existing-factor-viii-replacement-therapies-major-surgeries 2024-12-13T10:30:47+01:00 0.5 https://sciencelibrary.sobi.com/clinical-outcomes-over-2-years-once-weekly-efanesoctocog-alfa-treatment-children-severe-hemophilia 2024-12-12T15:26:28+01:00 0.5 https://sciencelibrary.sobi.com/real-world-effectiveness-and-usage-recombinant-factor-viii-fc-interim-analysis-adults-48-month 2025-02-05T06:50:10+01:00 0.5 https://sciencelibrary.sobi.com/emapalumab-treatment-adult-patients-malignancy-associated-hemophagocytic-lymphohistiocytosis-mhlh 2024-12-13T15:28:03+01:00 0.5 https://sciencelibrary.sobi.com/hematologic-improvement-experienced-pacritinib-treated-patients-myelofibrosis-real-world-clinical 2024-12-13T15:35:19+01:00 0.5 https://sciencelibrary.sobi.com/improvement-serum-albumin-measure-improved-metabolic-profile-pacritinib-treated-patients 2024-12-13T15:40:58+01:00 0.5 https://sciencelibrary.sobi.com/early-anemia-response-patients-myelofibrosis-treated-pacritinib-real-word-clinical-settings 2024-12-13T15:57:37+01:00 0.5 https://sciencelibrary.sobi.com/real-word-effectiveness-pacritinib-patients-myelofibrosis-who-have-thrombocytopenia-and-anemia 2024-12-13T16:03:26+01:00 0.5 https://sciencelibrary.sobi.com/european-retrospective-study-describe-real-world-outcomes-treatment-patterns-and-resource-use 2024-12-13T16:58:39+01:00 0.5 https://sciencelibrary.sobi.com/transplant-related-outcomes-patients-hemophagocytic-lymphohistiocytosis-treated-emapalumab-bridge 2024-12-13T17:07:08+01:00 0.5 https://sciencelibrary.sobi.com/patients-pts-optimized-hemophagocytic-lymphohistiocytosis-hlh-inflammatory-ohi-index-confirmed 2024-12-13T17:11:17+01:00 0.5 https://sciencelibrary.sobi.com/impact-thrombopoietin-receptor-agonists-and-adherence-instructions-treatment-chronic-primary-immune 2024-12-13T17:16:26+01:00 0.5 https://sciencelibrary.sobi.com/real-world-treatment-patterns-and-outcomes-patients-immune-thrombocytopenia-treated-avatrombopag 2024-12-13T17:20:09+01:00 0.5 https://sciencelibrary.sobi.com/results-phase-4-prospective-open-label-study-evaluating-safety-efficacy-and-treatment-satisfaction 2024-12-17T13:16:03+01:00 0.5 https://sciencelibrary.sobi.com/pegcetacoplan-post-transplant-recurrent-c3-glomerulopathy-or-immune-complex-membranoproliferative 2024-12-16T09:11:50+01:00 0.5 https://sciencelibrary.sobi.com/long-term-safety-and-efficacy-pegcetacoplan-patients-c3-glomerulopathy-or-primary-immune-complex 2024-12-16T09:17:51+01:00 0.5 https://sciencelibrary.sobi.com/efanesoctocog-alfa-perioperative-management-patients-severe-haemophilia-4-years-experience-xtend 2025-02-07T15:47:02+01:00 0.5 https://sciencelibrary.sobi.com/real-world-effectiveness-and-usage-recombinant-factor-viii-fc-interim-analysis-children-and 2025-02-05T06:51:26+01:00 0.5 https://sciencelibrary.sobi.com/real-world-survey-healthcare-resource-utilisation-and-physician-reported-burden-patients-primary 2024-12-16T10:49:33+01:00 0.5 https://sciencelibrary.sobi.com/real-world-survey-treatment-pathways-and-patterns-patients-primary-immune-complex 2024-12-16T10:58:40+01:00 0.5 https://sciencelibrary.sobi.com/treatment-bleeding-episodes-efanesoctocog-alfa-adults-and-adolescents-severe-haemophilia-second 2025-02-05T06:58:00+01:00 0.5 https://sciencelibrary.sobi.com/clinical-outcomes-over-3-years-efanesoctocog-alfa-adults-and-adolescents-severe-haemophilia 2025-02-05T06:55:26+01:00 0.5 https://sciencelibrary.sobi.com/clinical-outcomes-over-2-years-efanesoctocog-alfa-children-severe-haemophilia-european-results 2025-02-05T06:53:57+01:00 0.5 https://sciencelibrary.sobi.com/patient-characteristics-freedom-study-evaluating-physical-activity-and-joint-health-patients 2025-02-05T06:56:06+01:00 0.5 https://sciencelibrary.sobi.com/assessment-treatment-schedule-factor-viii-trough-level-and-area-under-curve-efanesoctocog-alfa-vs 2025-02-05T06:56:44+01:00 0.5 https://sciencelibrary.sobi.com/impact-hypothetical-switch-efanesoctocog-alfa-prophylaxis-bleeding-treatment-burden-and-area-under 2025-02-05T06:57:25+01:00 0.5 https://sciencelibrary.sobi.com/anchored-indirect-treatment-comparison-finds-comparable-effects-pegcetacoplan-and-iptacopan 2024-12-17T09:39:15+01:00 0.5 https://sciencelibrary.sobi.com/real-world-adherence-pegcetacoplan-paroxysmal-nocturnal-hemoglobinuria-compared-previously-reported 2024-12-17T09:48:05+01:00 0.5 https://sciencelibrary.sobi.com/thrombosis-and-encapsulated-bacterial-infection-rates-patients-paroxysmal-nocturnal-hemoglobinuria 2024-12-17T09:59:23+01:00 0.5 https://sciencelibrary.sobi.com/phase-1b-open-label-study-loncastuximab-tesirine-combination-other-anticancer-agents-patients 2024-12-17T17:58:35+01:00 0.5 https://sciencelibrary.sobi.com/reduced-iron-overload-pegcetacoplan-treatment-eculizumab-experienced-patients-paroxysmal-nocturnal 2024-12-17T13:49:21+01:00 0.5 https://sciencelibrary.sobi.com/first-report-complete-study-real-world-effectiveness-pegcetacoplan-patients-paroxysmal-nocturnal 2024-12-17T13:56:33+01:00 0.5 https://sciencelibrary.sobi.com/efficacy-pacritinib-patients-myelofibrosis-who-have-both-thrombocytopenia-and-anemia 2024-12-17T14:03:29+01:00 0.5 https://sciencelibrary.sobi.com/real-world-clinical-outcomes-complement-inhibitor-experienced-and-naive-paroxysmal-nocturnal 2024-12-17T14:39:04+01:00 0.5 https://sciencelibrary.sobi.com/impact-pacritinib-symptoms-thrombocytopenia-and-myelofibrosis-who-require-red-blood-cell 2024-12-17T14:11:21+01:00 0.5 https://sciencelibrary.sobi.com/real-world-treatment-patterns-and-outcomes-patients-myelofibrosis-treated-pacritinib-united-states 2024-12-17T14:43:21+01:00 0.5 https://sciencelibrary.sobi.com/lotis-5-ongoing-phase-3-randomized-study-loncastuximab-tesirine-rituximab-lonca-r-versus 2025-01-06T10:56:32+01:00 0.5 https://sciencelibrary.sobi.com/injection-site-reactions-adult-patients-paroxysmal-nocturnal-hemoglobinuria-who-received 2024-12-17T14:57:44+01:00 0.5 https://sciencelibrary.sobi.com/long-term-outcomes-pegcetacoplan-treatment-patients-paroxysmal-nocturnal-hemoglobinuria-and 2024-12-17T15:05:14+01:00 0.5 https://sciencelibrary.sobi.com/thrombosis-and-meningococcal-infection-rates-pegcetacoplan-patients-paroxysmal-nocturnal 2024-12-17T15:10:03+01:00 0.5 https://sciencelibrary.sobi.com/efficacy-and-safety-intensive-pegcetacoplan-dosing-treatment-acute-hemolysis-patients-paroxysmal 2024-12-17T15:14:25+01:00 0.5 https://sciencelibrary.sobi.com/characterization-clinically-significant-breakthrough-hemolysis-patients-paroxysmal-nocturnal 2024-12-19T11:20:30+01:00 0.5 https://sciencelibrary.sobi.com/improvement-iron-overload-pegcetacoplan-therapy-patients-paroxysmal-nocturnal-hemoglobinuria 2024-12-17T15:35:55+01:00 0.5 https://sciencelibrary.sobi.com/interferon-gamma-activity-impaired-haematopoietic-stem-cell-hsc-proliferation-and-graft-versus-host 2024-12-20T15:39:44+01:00 0.5 https://sciencelibrary.sobi.com/predictive-factors-graft-failure-adult-and-paediatric-patients-malignant-and-non-malignant-disease 2024-12-20T15:41:02+01:00 0.5 https://sciencelibrary.sobi.com/long-term-improvements-serum-uric-acid-levels-gout-symptoms-and-safety-12-months-sel-212-gout 2025-01-08T16:13:32+01:00 0.5 https://sciencelibrary.sobi.com/once-monthly-sel-212-demonstrates-efficacy-and-safety-6-months-gout-refractory-conventional-therapy 2025-01-08T16:13:32+01:00 0.5 https://sciencelibrary.sobi.com/health-related-quality-life-hrqol-and-other-secondary-clinical-outcomes-adults-gout-refractory 2025-01-08T16:13:32+01:00 0.5 https://sciencelibrary.sobi.com/efficacy-and-safety-emapalumab-children-and-adults-macrophage-activation-syndrome-mas-stills 2025-03-13T10:25:15+01:00 0.5 https://sciencelibrary.sobi.com/pacritinib-patients-intermediate-1-risk-myelofibrosis-outcomes-post-hoc-analysis-two-phase-3 2025-03-28T10:13:36+01:00 0.5 https://sciencelibrary.sobi.com/two-year-clinical-outcomes-once-weekly-efanesoctocog-alfa-prophylaxis-children-severe-hemophilia 2025-02-07T15:45:09+01:00 0.5 https://sciencelibrary.sobi.com/pegcetacoplan-adolescents-c3g-or-primary-ic-mpgn-valiant-phase-3-double-blind-placebo-controlled 2025-02-22T09:01:08+01:00 0.5 https://sciencelibrary.sobi.com/plain-language-summary-association-between-joint-health-and-patient-reported-quality-life-outcomes 2025-04-24T15:17:57+02:00 0.5 https://sciencelibrary.sobi.com/plain-language-summary-efanesoctocog-alfa-treatment-outcomes-over-3-years-adults-adolescents-severe 2025-04-22T14:31:59+02:00 0.5 https://sciencelibrary.sobi.com/plain-language-summary-two-year-results-weekly-efanesoctocog-alfa-treatment-children-severe 2025-04-22T14:31:05+02:00 0.5 https://sciencelibrary.sobi.com/efanesoctocog-alfa-perioperative-management-dental-surgery-participants-severe-hemophilia-4-years 2025-04-23T14:59:09+02:00 0.5 https://sciencelibrary.sobi.com/long-term-outcomes-prophylaxis-efanesoctocog-alfa-adults-and-adolescents-previously-treated-demand 2025-04-22T14:32:51+02:00 0.5 https://sciencelibrary.sobi.com/shine-study-design-interventional-open-label-phase-4-study-investigating-changes-synovial 2025-04-22T14:29:34+02:00 0.5 https://sciencelibrary.sobi.com/move-study-easily-explained-value-regular-joint-assessments-individuals-haemophilia 2025-04-22T10:50:43+02:00 0.5 https://sciencelibrary.sobi.com/emapalumab-treatment-anticipated-clinical-benefit-sepsis-driven-interferon-gamma-endotype-embrace 2025-02-24T05:40:25+01:00 0.5 https://sciencelibrary.sobi.com/patient-caregiver-and-physician-perspectives-burden-disease-chronic-refractory-gout-and-its 2025-05-16T11:08:43+02:00 0.5 https://sciencelibrary.sobi.com/entering-new-era-protection-haemophilia 2025-03-14T12:10:04+01:00 0.5 https://sciencelibrary.sobi.com/clinical-outcomes-over-3-years-once-weekly-efanesoctocog-alfa-treatment-adults-and-adolescents-0 2025-03-17T08:45:54+01:00 0.5 https://sciencelibrary.sobi.com/clinical-outcomes-over-2-years-once-weekly-efanesoctocog-alfa-treatment-children-north-america 2025-03-17T08:49:01+01:00 0.5 https://sciencelibrary.sobi.com/efanesoctocog-alfa-perioperative-management-patients-severe-hemophilia-4-years-experience-xtend 2025-03-17T08:53:38+01:00 0.5 https://sciencelibrary.sobi.com/synoviiius-prospective-interventional-study-effectiveness-efanesoctocog-alfa-prophylaxis-synovial 2025-03-17T08:47:26+01:00 0.5 https://sciencelibrary.sobi.com/emapalumab-treatment-anticipated-clinical-benefit-sepsis-driven-interferon-gamma-endotype-embrace-0 2025-03-28T08:37:28+01:00 0.5 https://sciencelibrary.sobi.com/nanoencapsulated-sirolimus-plus-pegadricase-nasp-demonstrates-reduction-gout-flares-results-phase-3 2025-05-01T18:18:26+02:00 0.5 https://sciencelibrary.sobi.com/reduction-tophi-observed-patients-chronic-refractory-gout-treated-nasp-results-phase-3-dissolve 2025-05-01T15:29:21+02:00 0.5 https://sciencelibrary.sobi.com/clinically-meaningful-response-avatrombopag-treatment-pediatric-immune-thrombocytopenia-post-hoc 2025-05-12T11:07:01+02:00 0.5 https://sciencelibrary.sobi.com/baseline-correlates-durability-avatrombopag-response-pediatric-immune-thrombocytopenia 2025-05-12T11:10:05+02:00 0.5 https://sciencelibrary.sobi.com/consensus-management-thrombotic-risk-people-primary-itp-uk 2025-05-06T11:38:08+02:00 0.5 https://sciencelibrary.sobi.com/thrombosis-and-encapsulated-bacterial-infection-rates-patients-paroxysmal-nocturnal-0 2025-05-15T10:48:21+02:00 0.5 https://sciencelibrary.sobi.com/patient-satisfaction-use-complement-inhibitor-injector-paroxysmal-nocturnal-hemoglobinuria-united 2025-05-15T10:45:08+02:00 0.5 https://sciencelibrary.sobi.com/reduced-iron-overload-pegcetacoplan-treatment-eculizumab-experienced-patients-paroxysmal-0 2025-05-15T10:47:04+02:00 0.5 https://sciencelibrary.sobi.com/real-world-adherence-pegcetacoplan-paroxysmal-nocturnal-hemoglobinuria-compared-previously-0 2025-05-15T10:49:35+02:00 0.5 https://sciencelibrary.sobi.com/qsp-modeling-loncastuximab-tesirine-lpyl-combined-t-cell-dependent-bispecific-antibodies-bridges 2025-06-02T09:53:53+02:00 0.5 https://sciencelibrary.sobi.com/variations-chronic-refractory-gout-management-between-rheumatologists-and-nephrologists 2025-06-11T08:12:02+02:00 0.5 https://sciencelibrary.sobi.com/pegcetacoplan-demonstrates-clinically-significant-responses-c3g-and-primary-idiopathic-ic-mpgn 2025-06-06T07:30:56+02:00 0.5 https://sciencelibrary.sobi.com/pegcetacoplan-treatment-effect-patients-nephrotic-range-proteinuria-results-valiant-phase-3-study 2025-06-06T07:29:35+02:00 0.5 https://sciencelibrary.sobi.com/targeted-treatment-pegcetacoplan-adolescents-c3g-or-primary-idiopathic-ic-mpgn-valiant-phase-3 2025-06-06T07:31:59+02:00 0.5 https://sciencelibrary.sobi.com/pegcetacoplan-treatment-appears-halt-disease-progression-c3g-and-primary-idiopathic-ic-mpgn 2025-06-13T08:40:12+02:00 0.5 https://sciencelibrary.sobi.com/targeted-treatment-pegcetacoplan-post-transplant-recurrent-c3g-or-primary-idiopathic-ic-mpgn 2025-06-13T08:43:47+02:00 0.5 https://sciencelibrary.sobi.com/thematic-analysis-healthcare-provider-perspectives-care-pathway-and-unmet-needs-c3g-and-primary-ic 2025-06-13T08:44:28+02:00 0.5 https://sciencelibrary.sobi.com/association-between-proteinuria-and-clinically-meaningful-endpoints-patients-c3g-ic-mpgn-delphi 2025-06-13T08:44:13+02:00 0.5 https://sciencelibrary.sobi.com/injection-site-reactions-adults-paroxysmal-nocturnal-haemoglobinuria-receiving-subcutaneous 2025-05-06T17:02:52+02:00 0.5 https://sciencelibrary.sobi.com/collaborative-initiative-national-pnh-service-survey-results-pegcetacoplan-patient-support 2025-05-06T17:01:00+02:00 0.5 https://sciencelibrary.sobi.com/challenges-medication-adherence-slowly-progressing-diseases 2025-06-14T16:30:42+02:00 0.5 https://sciencelibrary.sobi.com/primary-hlh-survey-study-pharmacists-practice-patterns-and-perceptions 2025-05-12T11:11:00+02:00 0.5 https://sciencelibrary.sobi.com/practice-patterns-and-adherence-treatment-guidance-management-hlhmas-associated-sjia-or-aosd 2025-04-14T08:52:13+02:00 0.5 https://sciencelibrary.sobi.com/pegcetacoplan-c3g-and-primary-idiopathic-ic-mpgn-52-week-results-phase-3-valiant-trial-show 2025-06-06T14:58:29+02:00 0.5 https://sciencelibrary.sobi.com/paxis-randomized-double-blind-placebo-controlled-dose-finding-phase-2-study-part-1-followed-open 2025-06-11T11:41:39+02:00 0.5 https://sciencelibrary.sobi.com/development-disease-activity-index-assessment-vexas-syndrome-vexas-dai 2025-06-11T11:40:30+02:00 0.5 https://sciencelibrary.sobi.com/development-consensus-definition-vexas-flare-use-clinical-research 2025-06-11T11:39:57+02:00 0.5 https://sciencelibrary.sobi.com/efficacy-and-safety-emapalumab-patients-macrophage-activation-syndrome-stills-disease-results 2025-05-03T23:55:38+02:00 0.5 https://sciencelibrary.sobi.com/when-autoinflammation-touches-heart 2025-04-30T12:38:34+02:00 0.5 https://sciencelibrary.sobi.com/differences-healthcare-resource-utilisation-between-3l-dlbcl-treatments-uk-hcp-survey 2025-04-30T19:04:33+02:00 0.5 https://sciencelibrary.sobi.com/valiant-pegcetacoplan-c3g-or-primary-idiopathic-ic-mpgn 2025-05-06T09:47:28+02:00 0.5 https://sciencelibrary.sobi.com/interim-analysis-ongoing-complete-study-real-world-effectiveness-pegcetacoplan-patients-paroxysmal 2025-06-27T12:06:18+02:00 0.5 https://sciencelibrary.sobi.com/early-response-complement-inhibitor-naive-patients-paroxysmal-nocturnal-hemoglobinuria-treated 2025-06-27T13:30:10+02:00 0.5 https://sciencelibrary.sobi.com/benefit-pegcetacoplan-patients-paroxysmal-nocturnal-hemoglobinuria-irrespective-baseline 2025-06-27T12:05:26+02:00 0.5 https://sciencelibrary.sobi.com/complete-study-single-arm-multicentre-observational-study-evaluate-effectiveness-pegcetacoplan 2025-05-13T10:26:08+02:00 0.5 https://sciencelibrary.sobi.com/advancing-haemophilia-care-new-levels-protection 2025-05-12T10:29:06+02:00 0.5 https://sciencelibrary.sobi.com/minor-surgeries-outcomes-efanesoctocog-alfa-4-years-experience-xtend-clinical-program 2025-06-23T16:58:38+02:00 0.5 https://sciencelibrary.sobi.com/major-surgical-outcomes-efanesoctocog-alfa-4-years-experience-xtend-clinical-program 2025-06-25T10:30:17+02:00 0.5 https://sciencelibrary.sobi.com/treatment-bleeding-episodes-efanesoctocog-alfa-children-xtend-ed-second-interim-analysis 2025-06-23T10:05:28+02:00 0.5 https://sciencelibrary.sobi.com/addressing-unmet-medical-needs-and-health-inequities-haemophilia-expert-consensus-statements 2025-06-23T16:59:32+02:00 0.5 https://sciencelibrary.sobi.com/transfusion-related-cost-and-time-burden-offsets-patients-myelofibrosis-treated-pacritinib-compared 2025-05-31T17:18:46+02:00 0.5 https://sciencelibrary.sobi.com/treatment-outcomes-pacritinib-patients-myelofibrosis-and-platelets-50-x109l-united-states 2025-05-31T17:15:06+02:00 0.5 https://sciencelibrary.sobi.com/prevalence-cytopenic-myelofibrosis-united-states 2025-05-31T17:14:34+02:00 0.5 https://sciencelibrary.sobi.com/hematologic-response-patients-myelofibrosis-treated-pacritinib-real-word-clinical-settings 2025-05-31T17:16:28+02:00 0.5 https://sciencelibrary.sobi.com/cytopenia-associated-real-world-disease-progression-and-diminished-survival-patients-myelofibrosis 2025-06-16T10:58:46+02:00 0.5 https://sciencelibrary.sobi.com/hematologic-improvement-experienced-pacritinib-treated-patients-myelofibrosis-real-world-clinical-0 2025-06-27T13:29:20+02:00 0.5 https://sciencelibrary.sobi.com/efficacy-pacritinib-vs-momelotinib-patients-thrombocytopenic-mf-matched-adjusted-indicated 2025-06-27T13:28:38+02:00 0.5 https://sciencelibrary.sobi.com/extravascular-distribution-factor-ix-evidence-and-relevance-hemophilia-b-replacement-therapy 2025-06-23T12:54:45+02:00 0.5 https://sciencelibrary.sobi.com/transfusion-related-cost-and-time-burden-offsets-patients-myelofibrosis-treated-pacritinib-0 2025-06-27T13:27:42+02:00 0.5 https://sciencelibrary.sobi.com/real-world-effectiveness-pacritinib-patients-myelofibrosis-who-have-thrombocytopenia-and-anemia 2025-06-27T11:56:54+02:00 0.5 https://sciencelibrary.sobi.com/real-world-treatment-patterns-and-clinical-outcomes-patients-myelofibrosis-treated-pacritinib-pac 2025-06-27T13:36:09+02:00 0.5 https://sciencelibrary.sobi.com/economic-burden-cytopenia-patients-myelofibrosis-analysis-us-national-administrative-claims 2025-06-16T10:58:14+02:00 0.5 https://sciencelibrary.sobi.com/real-world-effectiveness-and-usage-recombinant-factor-ix-fc-final-data-b-more-study 2025-06-23T12:54:00+02:00 0.5 https://sciencelibrary.sobi.com/monitoring-joint-health-hemophilia-patients-spain-updated-analysis-joint-us-project 2025-06-24T09:18:58+02:00 0.5 https://sciencelibrary.sobi.com/effectiveness-and-safety-avatrombopag-treatment-immune-thrombocytopenia-older-patients-and-those 2025-06-27T12:04:39+02:00 0.5 https://sciencelibrary.sobi.com/effectiveness-and-safety-avatrombopag-treatment-adults-newly-diagnosed-persistent-or-chronic-immune 2025-06-27T09:06:38+02:00 0.5 https://sciencelibrary.sobi.com/efficacy-and-safety-avatrombopag-treatment-pediatric-immune-thrombocytopenia-open-label-extension 2025-06-27T11:59:01+02:00 0.5 https://sciencelibrary.sobi.com/durability-response-avatrombopag-among-patients-primary-immune-thrombocytopenia-real-ava-20-real 2025-06-27T12:07:04+02:00 0.5 https://sciencelibrary.sobi.com/platelet-response-avatrombopag-among-patients-primary-immune-thrombocytopenia-who-switched 2025-06-27T13:24:45+02:00 0.5 https://sciencelibrary.sobi.com/clinically-meaningful-response-avatrombopag-phase-3b-trial-treatment-children-itp 2025-06-27T13:26:52+02:00 0.5 https://sciencelibrary.sobi.com/evaluation-efficacy-and-safety-avatrombopag-children-immune-thrombocytopenia-based-disease-duration 2025-06-27T12:03:47+02:00 0.5 https://sciencelibrary.sobi.com/response-avatrombopag-among-patients-chronic-and-persistent-primary-immune-thrombocytopenia-real 2025-06-27T09:07:29+02:00 0.5 https://sciencelibrary.sobi.com/real-world-treatment-patterns-clinical-outcomes-thrombopoietin-receptor-agonist-naive-patients 2025-06-27T12:02:42+02:00 0.5 https://sciencelibrary.sobi.com/cracking-complement-sequence 2025-06-16T08:22:11+02:00 0.5 https://sciencelibrary.sobi.com/initial-results-lotis-7-phase-1b-study-loncastuximab-tesirine-plus-glofitamab-patients 2025-06-27T12:00:29+02:00 0.5 https://sciencelibrary.sobi.com/updated-safety-run-results-lotis-5-phase-3-randomized-trial-loncastuximab-tesirine-rituximab-versus 2025-08-29T10:42:41+02:00 0.5 https://sciencelibrary.sobi.com/emapalumab-patients-primary-hemophagocytic-lymphohistiocytosis-efficacy-and-safety-outcomes 2025-06-13T09:49:56+02:00 0.5 https://sciencelibrary.sobi.com/benefit-assessment-pegcetacoplan-dose-increase-phase-3-pegasus-trial-pnh-patients-difficult-control 2025-06-27T11:55:50+02:00 0.5 https://sciencelibrary.sobi.com/exposure-safety-analysis-two-clinical-trials-emapalumab-patients-macrophage-activation-syndrome 2025-06-13T09:42:46+02:00 0.5 https://sciencelibrary.sobi.com/real-world-outcomes-avatrombopag-treatment-primary-itp-stratified-prior-tpo-ra-exposure 2025-06-24T22:00:58+02:00 0.5 https://sciencelibrary.sobi.com/analysis-baseline-influences-platelet-response-avatrombopag-ava-phase-3b-multicenter-randomized 2025-06-24T22:10:16+02:00 0.5 https://sciencelibrary.sobi.com/evaluation-efficacy-and-safety-avatrombopag-children-itp-based-disease-duration 2025-06-24T09:36:51+02:00 0.5 https://sciencelibrary.sobi.com/joint-health-outcomes-efanesoctocog-alfa-adultsadolescents-xtend-1-continuing-xtend-ed 2025-06-24T17:24:45+02:00 0.5 https://sciencelibrary.sobi.com/valiant-randomized-multicenter-double-blind-placebo-controlled-phase-3-trial-pegcetacoplan-patients 2025-06-14T16:26:47+02:00 0.5 https://sciencelibrary.sobi.com/association-between-fix-levels-bleeding-rates-hemophilia-b-patients-receiving-rfixfc-or-n9-gp 2025-06-23T12:53:07+02:00 0.5 https://sciencelibrary.sobi.com/efficacy-and-safety-emapalumab-patients-macrophage-activation-syndrome-stills-disease-results-0 2025-06-13T09:58:56+02:00 0.5 https://sciencelibrary.sobi.com/putting-your-vexas-goggles-seeing-whats-plain-sight 2025-07-10T10:46:35+02:00 0.5 https://sciencelibrary.sobi.com/real-world-treatment-patterns-and-outcomes-patients-myelofibrosis-treated-pacritinib-previously 2025-09-03T08:54:59+02:00 0.5 https://sciencelibrary.sobi.com/initial-results-lotis-7-phase-1b-study-loncastuximab-tesirine-plus-glofitamab-patients-0 2025-06-20T16:03:35+02:00 0.5 https://sciencelibrary.sobi.com/observational-study-prophylactic-efanesoctocog-alfa-joint-health-hemophilia-protect-alt 2025-06-24T17:26:31+02:00 0.5 https://sciencelibrary.sobi.com/long-term-observational-joint-health-study-patients-initiating-efanesoctocog-alfa-baseline-data 2025-06-24T17:27:55+02:00 0.5 https://sciencelibrary.sobi.com/dissecting-treatment-sequencing-relapsedrefractory-diffuse-large-b-cell-lymphoma-laboratory-real 2025-06-27T13:59:40+02:00 0.5 https://sciencelibrary.sobi.com/treatment-sequencing-rr-dlbcl-dissecting-emerging-challenge-bench-bedside 2025-07-09T21:40:14+02:00 0.5 https://sciencelibrary.sobi.com/advancing-therapeutic-knowledge-paroxysmal-nocturnal-haemoglobinuria-reshaping-disease-management 2025-06-27T13:55:18+02:00 0.5 https://sciencelibrary.sobi.com/boosting-platelets-expert-approaches-adult-immune-thrombocytopenia-itp 2025-07-09T21:50:55+02:00 0.5 https://sciencelibrary.sobi.com/changes-pharmacodynamic-markers-pd-response-emapalumab-children-and-adults-macrophage-activation 2025-09-19T03:37:54+02:00 0.5 https://sciencelibrary.sobi.com/efficacy-and-safety-emapalumab-treating-macrophage-activation-syndrome-stills-disease-pooled 2025-09-03T08:53:19+02:00 0.5 https://sciencelibrary.sobi.com/cytopenia-associated-real-world-disease-progression-and-diminished-survival-patients-0 2025-09-03T08:56:58+02:00 0.5 https://sciencelibrary.sobi.com/real-world-effectiveness-and-usage-recombinant-factor-ix-fc-rfixfc-haemophilia-b-age-groups-final-b 2025-09-12T08:27:07+02:00 0.5 https://sciencelibrary.sobi.com/hematologic-response-patients-myelofibrosis-treated-pacritinib-real-word-clinical-settings-0 2025-09-03T08:55:39+02:00 0.5 https://sciencelibrary.sobi.com/perioperative-management-efanesoctocog-alfa-patients-haemophilia-xtend-clinical-trial-programme 2025-09-12T14:18:30+02:00 0.5 https://sciencelibrary.sobi.com/joint-replacementrevision-surgery-outcomes-efanesoctocog-alfa-4-years-experience-xtend-clinical 2025-09-12T14:31:06+02:00 0.5 https://sciencelibrary.sobi.com/bleed-treatment-outcomes-xtend-ed-study-patients-aged-50-years-and-older 2025-09-12T14:15:43+02:00 0.5 https://sciencelibrary.sobi.com/pegcetacoplan-posttransplant-patients-complement-3-glomerulopathy-or-primary-idiopathic-immune 2025-09-22T12:07:07+02:00 0.5 https://sciencelibrary.sobi.com/effect-nanoencapsulated-sirolimus-plus-pegadricase-nasp-kidney-outcomes-results-phase-3-dissolve 2025-11-05T16:25:34+01:00 0.5 https://sciencelibrary.sobi.com/management-mas-and-stills-disease-challenges-and-opportunities 2025-09-12T11:05:58+02:00 0.5 https://sciencelibrary.sobi.com/pegcetacoplan-post-transplant-patients-complement-3-glomerulopathy-or-primary-idiopathic-immune 2025-09-22T12:06:45+02:00 0.5 https://sciencelibrary.sobi.com/pegcetacoplan-paediatric-patients-c3-glomerulopathy-or-primary-immune-complex-mediated 2025-10-17T14:51:59+02:00 0.5 https://sciencelibrary.sobi.com/pegcetacoplan-halts-disease-progression-and-reduces-proteinuria-paediatric-patients-c3g-and-primary 2025-10-17T14:50:24+02:00 0.5 https://sciencelibrary.sobi.com/one-year-efficacy-and-safety-avatrombopag-chronic-immune-thrombocytopenia-japanese-adults 2025-11-13T10:28:34+01:00 0.5 https://sciencelibrary.sobi.com/emapalumab-treatment-patients-differing-presentations-macrophage-activation-syndrome-mas-secondary 2025-10-28T09:46:32+01:00 0.5 https://sciencelibrary.sobi.com/baseline-pharmacodynamic-markers-and-response-emapalumab-children-and-adults-macrophage-activation 2025-10-27T17:29:03+01:00 0.5 https://sciencelibrary.sobi.com/economic-burden-macrophage-activation-syndrome-mas-patients-stills-disease-systemic-juvenile 2025-10-30T10:53:56+01:00 0.5 https://sciencelibrary.sobi.com/development-disease-activity-index-assessment-vexas-syndrome-vexas-dai-0 2025-10-27T17:27:39+01:00 0.5 https://sciencelibrary.sobi.com/paxis-randomized-double-blind-placebo-controlled-dose-finding-phase-2-study-part-1-followed-open-0 2025-10-30T10:52:16+01:00 0.5 https://sciencelibrary.sobi.com/development-consensus-definition-vexas-flare-use-clinical-research-0 2025-10-27T17:28:19+01:00 0.5 https://sciencelibrary.sobi.com/nanoencapsulated-sirolimus-plus-pegadricase-reduced-disease-burden-patients-uncontrolled-gout 2025-11-05T11:40:40+01:00 0.5 https://sciencelibrary.sobi.com/characterization-infusion-reactions-within-1-hour-treatment-nanoencapsulated-sirolimus-plus 2025-11-05T11:43:49+01:00 0.5 https://sciencelibrary.sobi.com/nanoencapsulated-sirolimus-plus-pegadricase-nasp-demonstrates-long-term-efficacy-and-safety 2025-11-05T11:44:45+01:00 0.5 https://sciencelibrary.sobi.com/healthcare-resource-utilization-patients-primary-immune-thrombocytopenia-treated-avatrombopag 2025-11-13T10:50:20+01:00 0.5 https://sciencelibrary.sobi.com/decoding-complement-c3g-and-primary-ic-mpgn-exploring-evolving-paths-care 2025-10-21T15:58:53+02:00 0.5 https://sciencelibrary.sobi.com/hemophagocytic-lymphohistiocytosis-hlh-survey-study-pharmacists-practice-patterns-and-perceptions 2025-10-21T10:11:02+02:00 0.5 https://sciencelibrary.sobi.com/use-emapalumab-associated-rapid-and-sustained-benefits-phlh-subgroups-including-cns-involvement-and 2025-12-03T09:53:06+01:00 0.5 https://sciencelibrary.sobi.com/emapalumab-induces-rapid-durable-responses-and-reliable-bridging-curative-hsct-patients-primary-hlh 2025-12-03T09:51:49+01:00 0.5 https://sciencelibrary.sobi.com/real-world-treatment-patterns-and-outcomes-patients-myelofibrosis-who-presented-thrombocytopenia 2025-12-03T09:57:23+01:00 0.5 https://sciencelibrary.sobi.com/pacritinib-patients-high-risk-myelofibrosis-outcomes-post-hoc-analyses-two-phase-3-studies 2025-12-03T09:59:58+01:00 0.5 https://sciencelibrary.sobi.com/real-world-treatment-patterns-and-clinical-outcomes-patients-myelofibrosis-treated-pacritinib-pac-0 2025-12-03T10:03:33+01:00 0.5 https://sciencelibrary.sobi.com/prospera-abnl-marro-002-randomized-phase-2-study-pacritinib-vs-hydroxyurea-patients-advanced 2025-12-03T10:01:00+01:00 0.5 https://sciencelibrary.sobi.com/treatment-patterns-and-outcomes-patients-myelofibrosis-treated-pacritinib-following-switch 2025-12-03T10:02:44+01:00 0.5 https://sciencelibrary.sobi.com/incidence-prevalence-and-clinical-outcomes-myelofibrosis-and-without-cytopenia-united-states 2025-12-03T10:05:43+01:00 0.5 https://sciencelibrary.sobi.com/economic-burden-cytopenia-patients-myelofibrosis-analysis-us-national-administrative-claims-0 2025-10-30T13:28:50+01:00 0.5 https://sciencelibrary.sobi.com/economic-burden-macrophage-activation-syndrome-mas-patients-stills-disease-systemic-juvenile-0 2026-01-19T11:18:41+01:00 0.5 https://sciencelibrary.sobi.com/transfusion-related-cost-and-time-burden-offsets-patients-myelofibrosis-treated-pacritinib-1 2025-10-30T13:32:45+01:00 0.5 https://sciencelibrary.sobi.com/nanoencapsulated-sirolimus-plus-pegadricase-nasp-demonstrates-reduction-gout-flares-results-phase-0 2025-11-05T11:54:35+01:00 0.5 https://sciencelibrary.sobi.com/care-pathway-and-treatment-patterns-patients-uncontrolled-gout-real-world-survey-physicians-united 2025-11-05T12:00:50+01:00 0.5 https://sciencelibrary.sobi.com/reduction-tophi-observed-patients-uncontrolled-gout-treated-nasp-results-phase-3-dissolve-studies 2025-11-05T12:07:34+01:00 0.5 https://sciencelibrary.sobi.com/real-world-survey-physicians-perspectives-uncontrolled-gout-and-gout-management-practices 2025-11-05T12:09:43+01:00 0.5 https://sciencelibrary.sobi.com/management-uncontrolled-gout-among-rheumatologists-findings-medical-chart-audit 2025-11-05T12:12:20+01:00 0.5 https://sciencelibrary.sobi.com/patient-and-caregiver-perspectives-burden-disease-uncontrolled-gout-cross-sectional-survey-study 2025-11-05T12:14:56+01:00 0.5 https://sciencelibrary.sobi.com/management-uncontrolled-gout-among-nephrology-professionals-findings-medical-chart-audit 2025-11-05T16:22:52+01:00 0.5 https://sciencelibrary.sobi.com/nanoencapsulated-sirolimus-plus-pegadricase-nasp-reduces-gout-clinical-manifestations-patients 2025-11-05T16:25:16+01:00 0.5 https://sciencelibrary.sobi.com/interim-analysis-complete-study-real-world-effectiveness-pegcetacoplan-patients-paroxysmal 2025-11-05T18:25:24+01:00 0.5 https://sciencelibrary.sobi.com/pegcetacoplan-52-weeks-results-sustained-proteinuria-reduction-remission-05-gg-and-normalization-02 2025-11-10T15:47:00+01:00 0.5 https://sciencelibrary.sobi.com/pegcetacoplan-52-weeks-maintained-proteinuria-reduction-regardless-immunosuppressant-use-or 2025-11-10T15:57:29+01:00 0.5 https://sciencelibrary.sobi.com/pegcetacoplan-versus-iptacopan-treatment-patients-c3-glomerulopathy-indirect-treatment-comparisons 2025-11-10T16:24:46+01:00 0.5 https://sciencelibrary.sobi.com/tirednessthats-main-thing-why-i-work-part-time-thematic-analysis-patient-perspectives-care-and 2025-11-10T16:29:39+01:00 0.5 https://sciencelibrary.sobi.com/human-factors-validation-pegcetacoplan-body-injector-demonstrates-ease-use-adolescents-c3 2025-11-10T16:34:34+01:00 0.5 https://sciencelibrary.sobi.com/pegcetacoplan-adolescents-and-adults-c3-glomerulopathy-or-primary-immune-complex 2025-11-10T16:38:54+01:00 0.5 https://sciencelibrary.sobi.com/clinical-outcomes-4-years-once-weekly-efanesoctocog-alfa-prophylaxis-previously-treated-adults 2025-12-02T14:13:27+01:00 0.5 https://sciencelibrary.sobi.com/understanding-unmet-needs-people-haemophilia-receiving-factor-and-non-factor-treatments 2025-12-02T14:19:12+01:00 0.5 https://sciencelibrary.sobi.com/real-world-experience-efanesoctocog-alfa-hemophilia-patients-us-retrospective-analysis 2025-12-02T14:18:17+01:00 0.5 https://sciencelibrary.sobi.com/patient-characteristics-treatment-patterns-and-bleeding-people-hemophilia-without-inhibitors 2025-12-02T14:16:25+01:00 0.5 https://sciencelibrary.sobi.com/quality-life-and-functional-improvements-efanesoctocog-alfa-patients-moderate-severe-hemophilia 2025-12-02T14:15:02+01:00 0.5 https://sciencelibrary.sobi.com/real-world-treatment-patterns-outcomes-among-patients-immune-thrombocytopenia-itp-who-switched 2025-11-28T16:24:49+01:00 0.5 https://sciencelibrary.sobi.com/real-world-safety-and-efficacy-avatrombopag-adults-immune-thrombocytopenia-systematic-review-and 2025-11-28T16:25:17+01:00 0.5 https://sciencelibrary.sobi.com/patient-reported-outcomes-avatrombopag-chronic-immune-thrombocytopenia-interim-analysis-phase-4 2025-11-28T16:24:22+01:00 0.5 https://sciencelibrary.sobi.com/consistent-benefits-pegcetacoplan-treatment-pnh-patients-and-without-history-aplastic-anemia-real 2025-12-09T12:13:42+01:00 0.5 https://sciencelibrary.sobi.com/real-world-clinical-characteristics-and-treatment-outcomes-pnh-patients-prescribed-pegcetacoplan 2025-12-09T12:19:09+01:00 0.5 https://sciencelibrary.sobi.com/early-results-ongoing-pegcetacoplan-silo-international-paroxysmal-nocturnal-hemoglobinuria-interest 2025-12-09T12:23:39+01:00 0.5 https://sciencelibrary.sobi.com/optimizing-pnh-treatment-complement-inhibitor-pegcetacoplan-case-report 2025-12-09T12:36:00+01:00 0.5 https://sciencelibrary.sobi.com/real-world-effectiveness-pegcetacoplan-paroxysmal-nocturnal-hemoglobinuria-systematic-review 2025-12-09T12:39:47+01:00 0.5 https://sciencelibrary.sobi.com/low-risk-meningococcal-and-encapsulated-bacteria-infections-systemically-administered-pegcetacoplan 2025-12-09T12:43:37+01:00 0.5 https://sciencelibrary.sobi.com/overview-treatment-advances-complement-inhibitors-patients-paroxysmal-nocturnal-hemoglobinuria 2025-12-09T12:49:52+01:00 0.5 https://sciencelibrary.sobi.com/user-experience-pegcetacoplan-body-injector-patients-paroxysmal-nocturnal-hemoglobinuria 2025-12-09T12:54:00+01:00 0.5 https://sciencelibrary.sobi.com/efanesoctocog-alfa-prophylaxis-people-severe-haemophilia-third-interim-results-xtend-ed-long-term 2026-03-31T13:13:45+02:00 0.5 https://sciencelibrary.sobi.com/physical-activity-and-efficacy-patients-severe-haemophilia-treated-efanesoctocog-alfa-12-month 2026-02-06T12:08:29+01:00 0.5 https://sciencelibrary.sobi.com/long-term-clinical-outcomes-efanesoctocog-alfa-patients-severe-haemophilia-european-results-third 2026-02-06T12:14:33+01:00 0.5 https://sciencelibrary.sobi.com/treatment-bleeding-episodes-efanesoctocog-alfa-adults-adolescents-and-children-severe-haemophilia 2026-02-06T12:13:44+01:00 0.5 https://sciencelibrary.sobi.com/assessment-joint-health-and-patient-physician-alignment-joint-damage-reports-cohort-people 2026-02-06T12:21:35+01:00 0.5 https://sciencelibrary.sobi.com/clinical-psychosocial-quality-life-outcomes-and-patient-physician-discrepancies-joint-damage 2026-02-06T12:21:08+01:00 0.5 https://sciencelibrary.sobi.com/real-world-effectiveness-and-usage-rfixfc-haemophilia-b-final-paediatric-data-b-more-study 2026-02-06T12:17:09+01:00 0.5 https://sciencelibrary.sobi.com/efficacy-and-safety-emapalumab-patients-macrophage-activation-syndrome-mas-systemic-lupus 2026-03-19T14:20:09+01:00 0.5 https://sciencelibrary.sobi.com/prospective-validation-sepsis-endotype-classification-results-embrace-trial 2026-03-17T08:23:51+01:00 0.5 https://sciencelibrary.sobi.com/impact-elevated-serum-urate-levels-and-tophi-hrqol-and-daily-functioning-patients-uncontrolled-gout 2026-02-10T15:26:22+01:00 0.5 https://sciencelibrary.sobi.com/emapalumab-associated-rapid-and-sustained-benefits-phlh-subgroups-including-cns-involvement-and 2026-03-22T10:27:49+01:00 0.5 https://sciencelibrary.sobi.com/emapalumab-induces-rapid-durable-responses-and-reliable-bridging-curative-hsct-patients-primary-0 2026-03-22T10:29:30+01:00 0.5 https://sciencelibrary.sobi.com/physical-activity-and-bleed-prevention-people-severe-haemophilia-treated-once-weekly-efanesoctocog 2026-03-05T11:25:10+01:00 0.5 https://sciencelibrary.sobi.com/joint-health-outcomes-efanesoctocog-alfa-adultsadolescents-xtend-1-continuing-xtend-ed-plain 2026-03-05T11:18:24+01:00 0.5 https://sciencelibrary.sobi.com/hemophilia-life-stages-and-changes-global-survey-people-hemophilia-caregivers-and-hematologists 2026-03-05T10:50:07+01:00 0.5 https://sciencelibrary.sobi.com/plain-language-summary-what-extravascular-distribution-factor-ix-and-how-does-it-affect-management 2026-03-05T10:57:12+01:00 0.5 https://sciencelibrary.sobi.com/efficacy-pegcetacoplan-patients-lower-baseline-proteinuria-subgroup-analysis-valiant-trial 2026-03-30T17:20:58+02:00 0.5 https://sciencelibrary.sobi.com/clinical-efficacy-pegcetacoplan-versus-iptacopan-patients-c3-glomerulopathy-indirect-treatment 2026-03-30T17:19:30+02:00 0.5 https://sciencelibrary.sobi.com/baseline-pharmacodynamic-markers-and-response-emapalumab-children-and-adults-macrophage-0 2026-03-23T10:23:14+01:00 0.5 https://sciencelibrary.sobi.com/emapalumab-treatment-patients-differing-presentations-macrophage-activation-syndrome-mas-0 2026-03-23T10:28:37+01:00 0.5 https://sciencelibrary.sobi.com/efficacy-and-safety-emapalumab-patients-macrophage-activation-syndrome-mas-systemic-lupus-0 2026-03-23T10:31:50+01:00 0.5 https://sciencelibrary.sobi.com/pegcetacoplan-population-pharmacokinetic-and-exposure-response-pediatric-and-adult-patients-c3g-and 2026-03-31T13:49:33+02:00 0.5 https://sciencelibrary.sobi.com/science-library 2025-01-07T15:55:52+01:00 0.5 https://sciencelibrary.sobi.com/faqs 2024-10-28T09:45:06+01:00 0.5 https://sciencelibrary.sobi.com/congresses 2024-10-28T09:48:36+01:00 0.5 https://sciencelibrary.sobi.com/subscribe 2024-11-28T15:11:01+01:00 0.5 https://sciencelibrary.sobi.com/privacy-policy 2024-11-28T17:11:00+01:00 0.5 https://sciencelibrary.sobi.com/terms-use 2024-10-09T08:24:47+02:00 0.5 https://sciencelibrary.sobi.com/cookie-policy 2024-11-29T11:36:10+01:00 0.5